Rockwell Medical Inc.’s Triferic, an iron replacement product delivered via dialysate, is now commercially available throughout the United States.

The drug is introduced into bicarbonate concentrate, on-site at the dialysis clinic, and subsequently mixed into dialysate. Recent studies have shown that Triferic replaces iron loss, maintains hemoglobin, and does not increase iron stores.

“IV iron is generally given weekly and by design is trapped in the patient’s liver, which leads to iron overload and the functional iron deficiency that is prevalent in patients today,” said Robert L. Chioini, Founder, Chairman and Chief Executive Officer of Rockwell Medical. “Triferic however replaces iron at every patient treatment and maintains hemoglobin concentration without increasing iron stores, because the iron is used immediately and not stored in the liver.”